Introduction
The UK and Germany are the two largest medical cannabis markets in Europe, but their regulatory frameworks differ significantly. Germany's Cannabis Act (CanG) reforms in 2024 fundamentally changed its approach, while the UK's framework remains rooted in controlled drug scheduling from 2018. This guide compares the two systems side by side for operators considering market entry, cross-border supply or dual-jurisdiction operations.
Legal Status and Classification
In the UK, cannabis remains a Class B controlled drug under the Misuse of Drugs Act 1971. CBPMs are scheduled under Schedule 2 of the Misuse of Drugs Regulations 2001.
In Germany, cannabis was removed entirely from the Narcotics Act (BtMG) in April 2024 under the CanG reforms. It is now regulated under the Medical Cannabis Act (MedCanG) as a standard pharmaceutical product rather than a narcotic.
Fundamental Difference
Regulatory Bodies
UK: MHRA (pharmaceutical regulation), Home Office DFLU (controlled drug licensing), GPhC (pharmacy regulation), CQC (clinic regulation).
Germany: BfArM (pharmaceutical regulation and licensing under MedCanG), state-level health authorities (pharmacy and clinic oversight).
Practical Impact
Browse Verified UK Operators
Find licence-verified importers, manufacturers and distributors in the MedCannaSource directory.
Browse DirectoryPrescribing Framework
UK: CBPMs can only be prescribed by doctors on the GMC Specialist Register. GPs cannot prescribe without exceptional funding approval from their Integrated Care Board. Most prescriptions are private.
Germany: Any doctor can prescribe medical cannabis since the MedCanG removed the narcotic prescription requirement. However, a 2025 amendment now mandates in-person consultations for initial prescriptions, with annual in-person reviews for follow-ups. This was a response to rapid growth in telemedicine prescribing platforms.
The German system is significantly more accessible for patients, which is why patient numbers have grown much faster.
Insurance and Reimbursement
UK: No meaningful NHS coverage. Only three patients are known to have received NHS-funded cannabis prescriptions. Patients pay privately, typically £150–400 per month.
Germany: Medical cannabis has been covered by statutory health insurance (GKV) since 2017. Insurers can reject applications but must provide clinical justification.
Market Impact
Import Requirements
UK: HO CD Import Licence per shipment + WDA(H) or MIA + 28-day MHRA notification. Typical processing: 4–8 weeks.
Germany: BfArM Einfuhrerlaubnis (import permit). Processing times have improved to 6–8 weeks for established corridors. The EU tender process for domestic cultivation contracts has been removed under MedCanG, and companies can now market and distribute their own harvest.
Germany's import volumes surged 400% from 19 to 80 tonnes in H1 2025.
Download the GMP Self-Inspection Checklist
72-item checklist aligned with MHRA expectations — free to download from the Compliance Toolkit.
Go to ToolkitManufacturing and GMP
Both markets require EU GMP compliance. UK manufacturers need an MIA or Specials Licence from the MHRA. German manufacturers need a Herstellungserlaubnis from BfArM. The practical standards are essentially identical since both follow PIC/S GMP guidelines.
The key difference is that Germany now allows domestic cultivators to self-distribute, while UK cultivation remains extremely restricted with very few Home Office licences granted.
Market Size and Growth
UK: Estimated 340,000 patients, almost entirely private prescriptions. Market growing but constrained by lack of NHS coverage and complex import procedures.
Germany: Over 500,000 patients and growing rapidly. Insurance coverage drives accessibility. Medical cannabis imports reached 80 tonnes in H1 2025 alone. Germany is now the largest medical cannabis import market in Europe.
Advertising and Promotion
UK: Strict prohibition on promotion of unlicensed medicines under HMR 2012. No public advertising of CBPMs permitted.
Germany: Heilmittelwerbegesetz (HWG) prohibits lay advertising of prescription medicines. Similar restrictions but enforcement approach differs. Both markets prohibit direct-to-consumer advertising of medical cannabis.
Browse Verified UK Operators
Find licence-verified importers, manufacturers and distributors in the MedCannaSource directory.
Browse DirectoryKey Differences Summary
| Aspect | UK | Germany |
|---|---|---|
| Legal classification | Class B controlled drug (Schedule 2) | Pharmaceutical product (MedCanG) |
| Primary regulator | MHRA + Home Office | BfArM |
| Who can prescribe | Specialist doctors only | Any doctor |
| Insurance coverage | Almost none (private) | GKV statutory coverage |
| Import licence type | Per-shipment HO + WDA/MIA | BfArM Einfuhrerlaubnis |
| Import processing | 4–8 weeks | 6–8 weeks |
| GMP standard | EU GMP / PIC/S | EU GMP / PIC/S |
| Domestic cultivation | Extremely restricted | Expanding rapidly |
| Patient population | ~340,000 | 500,000+ |
| Market trajectory | Growing (constrained) | Growing rapidly |
Implications for Cross-Border Operators
Operators considering both markets should note that MHRA and BfArM GMP inspections are mutually recognised to a degree, but each market requires its own import and distribution licences. A WDA(H) in the UK does not authorise distribution in Germany, and vice versa.
The most efficient approach for dual-market entry is to establish manufacturing or distribution in one jurisdiction and apply for import authorisation in the other. The Portugal–Germany and Canada–UK corridors are the most established supply routes.
Compare tracked jurisdictions side by side
Download the Regulatory Comparison Matrix from the MedCannaSource Compliance Toolkit.
Go to ToolkitGet the Weekly Compliance Digest
Every Monday, regulatory changes, licence grants, and market intelligence across tracked jurisdictions.